[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541729":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":31,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":31,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Revulizumab Treatment","EXPERIMENTAL","Subjects will receive an single-dose infusion of Ravulizumab.",[13],"Drug: Ravulizumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ravulizumab","Intravenous infusion 100 mg\u002Fml",[9],[21],"Ultomiris",[23],{"name":24,"affiliation":5,"role":25},"Maria Lourdes Gonzalez Suarez, MD, PhD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":31},"Gonzalez Suarez","CONTACT","507-284-2511",null,[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Mayo Clinic Minnesota","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-92.4699,44.02163,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":31,"email":51},"Maria L. Gonzalez Suarez, MD,PhD","5072844083","gonzalezsuarez.maria@mayo.edu",{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Maria Lourdes Gonzalez Suarez","Principal Investigator","100541729","phase-2-ravulizumab-in-pregnancies-complicated-by-severe-hypertensive-disorders-100541729",false,"NCT06333652","Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders","Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders","Inclusion Criteria:\n\n* Individuals with \\\u003C 34 0\u002F7 weeks of gestation.\n* Individuals with severe preeclampsia or HELLP features.\n\nExclusion Criteria:\n\n* Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).\n* Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\\\u003C23 0\u002F7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.","FEMALE","18 Years","50 Years",{"count":66,"type":67},14,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.",[73],"Preeclampsia",[75,76,77],"Hemolysis","Elevated Liver enzymes","Low Platelets","2026-04-23",{"date":80,"type":81},"2026-04-28","ACTUAL",{"date":83,"type":67},"2026-09-01",{"date":85,"type":67},"2028-12-31",{"name":5,"class":6},1]